A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants.

    Project Details

    StatusFinished
    Effective start/end date8/09/197/09/20

    Funding

    • GlaxoSmithKline: AUD42,304.00
    • GlaxoSmithKline: AUD92,332.00